Newborn Genomic Screening Enables More Lifesaving Diagnoses

The standard heel-prick test screens for just 32 conditions, leaving many treatable diseases undetected. Now, a new genomic-based approach demonstrates the potential to diagnose hundreds of additional childhood conditions within two weeks of birth, paving the way for faster treatment and improved outcomes.

In a study involving 1,000 newborns, researchers at the Murdoch Children’s Research Institute (MCRI, Melbourne, Australia) and Victorian Clinical Genetics Services (VCGS, Melbourne, Australia) evaluated the integration of genomic sequencing into newborn blood screening. Using the same blood sample collected for the heel-prick test, the researchers analyzed 605 genes linked to early-onset, severe, but treatable diseases.

The study identified 16 babies with a high likelihood of a genetic condition—only one of which would have been detected using current methods. One baby was diagnosed with hemophagocytic lymphohistiocytosis (HLH), a severe immunodeficiency disorder, allowing for immediate treatment and a successful bone marrow transplant.

Results from the BabyScreen+ trial showed that genomic screening is both technically feasible and acceptable to parents, with results available within 14 days. The study found that 99.5% of parents supported making the test universally available, and 93% said they would recommend it to others. The findings, published in Nature Medicine, highlight genomic testing’s superiority in identifying diseases that standard screening often misses.

Genomic newborn screening could expand the range of detectable conditions to include those linked to childhood cancers, heart disease, and neurological disorders. However, the researchers emphasize that issues such as cost, data storage, privacy, and lifelong consent will need to be addressed before widespread adoption can occur.

“Newborn screening for rare conditions is one of the most effective public health interventions. But the increased capacity of genomic medicine to diagnose and treat rare diseases has challenged the ability of newborn screening programs to keep pace,” said MCRI Professor Zornitza Stark. “Our study found incorporating genomic sequencing provides the opportunity to substantially expand the range of conditions screened for, including those that predispose people to childhood cancers, as well as cardiac and neurological disorders, not detectable with current standard technologies.”

Related Links:
MCRI
VCGS